Which sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor should be used as first‑line therapy for patients with heart failure with reduced ejection fraction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

First-Line SGLT2 Inhibitor for Heart Failure with Reduced Ejection Fraction

Either dapagliflozin 10 mg daily or empagliflozin 10 mg daily should be used as first-line SGLT2 inhibitor therapy for patients with heart failure with reduced ejection fraction (HFrEF), as both agents have equivalent strong evidence for reducing cardiovascular death and heart failure hospitalization. 1

Evidence-Based Recommendation

The most recent 2025 Canadian Cardiovascular Society/Canadian Heart Failure Society guidelines explicitly recommend both dapagliflozin and empagliflozin as first-line SGLT2 inhibitors for HFrEF with equal standing 2. The 2021 CCS/CHFS guidelines provide a Strong Recommendation with High-Quality Evidence that "an SGLT2 inhibitor, such as dapagliflozin or empagliflozin, be used in patients with HFrEF, with or without concomitant type 2 diabetes, to improve symptoms and quality of life and to reduce the risk of HF hospitalization and/or CV mortality" 1.

Dosing Specifications

Dapagliflozin:

  • Starting dose: 10 mg daily
  • Target dose: 10 mg daily (no titration needed) 2, 3

Empagliflozin:

  • Starting dose: 10 mg daily
  • Target dose: 10-25 mg daily 2, 3

Why Both Agents Are Equivalent

The landmark trials DAPA-HF (dapagliflozin) and EMPEROR-Reduced (empagliflozin) both demonstrated significant reductions in HF hospitalization and cardiovascular death in patients with HFrEF, regardless of diabetes status 1. A meta-analysis of these two trials showed consistent benefits: 13% reduction in all-cause death (HR 0.87,95% CI 0.77-0.98), 14% reduction in cardiovascular death (HR 0.86,95% CI 0.76-0.98), and 26% reduction in cardiovascular death or first HF hospitalization (HR 0.74,95% CI 0.68-0.82) 4. Importantly, tests for heterogeneity between the two trials were not significant, confirming equivalent efficacy 4.

Practical Selection Between the Two Agents

Since guidelines do not support a specific sequence or preference between dapagliflozin and empagliflozin 2, selection should be based on:

Choose Dapagliflozin if:

  • Patient has concomitant chronic kidney disease with albuminuria (eGFR 25-75 mL/min/1.73 m² with proteinuria), as DAPA-CKD trial showed 44% reduction in renal outcomes and 31% reduction in cardiovascular death or HF hospitalization 1
  • Simplicity is preferred (no titration required—start and stay at 10 mg daily)
  • Patient has eGFR 25-30 mL/min/1.73 m² (DAPA-HF excluded patients with eGFR <30, but dapagliflozin has specific renal protection data down to eGFR 25) 1

Choose Empagliflozin if:

  • Patient has type 2 diabetes with established atherosclerotic cardiovascular disease (broader diabetes indication) 1
  • Patient has eGFR 20-30 mL/min/1.73 m² (EMPEROR-Reduced excluded patients with eGFR <20 vs. <30 for DAPA-HF) 1
  • Dose flexibility is desired (can titrate from 10 to 25 mg if needed)

Either Agent Works Equally Well if:

  • Patient has HFrEF without the specific considerations above
  • Cost and formulary access are equivalent
  • Patient preference exists for once-daily dosing (both are once daily)

Critical Implementation Points

Start SGLT2 inhibitors early in the disease course. While the landmark trials initiated therapy on top of maximally tolerated guideline-directed medical therapy (GDMT), recognizing the significant residual risk in HFrEF patients, it is reasonable to start SGLT2 inhibitors early rather than waiting for complete GDMT optimization 1. The 2025 guidelines explicitly state that "the literature currently does not support a specific sequence to initiating therapy" and that SGLT2 inhibitors can be initiated in any order alongside other GDMT components 2.

No titration is required for dapagliflozin (start and maintain at 10 mg daily), while empagliflozin may be titrated from 10 to 25 mg daily based on tolerability 2, 3.

Safety Considerations and Monitoring

Common Pitfalls to Avoid:

Genital mycotic infections (GMIs) are the most common adverse effect (10-15% risk in women, higher in uncircumcised men and those with previous GMIs). These typically can be managed with antifungal drugs without discontinuing therapy 1.

Temporary eGFR reduction up to 15% may occur, which generally resolves within 1-3 months. Do not discontinue therapy for this expected hemodynamic effect 1.

eGFR thresholds:

  • EMPEROR-Reduced excluded eGFR <20 mL/min/1.73 m²
  • DAPA-HF excluded eGFR <30 mL/min/1.73 m²
  • Data supporting use with eGFR <30 mL/min/1.73 m² are very limited 1

Contraindications:

  • Type 1 diabetes (absolute contraindication) 1
  • End-stage renal disease requiring dialysis 5
  • Pregnancy or lactation 5

Monitoring Requirements:

Monitor for volume depletion, particularly in patients on high-dose diuretics or with borderline blood pressure. However, SGLT2 inhibitors enhance diuretic efficiency without adverse renal impacts and actually reduce hypotension risk compared to concerns 6.

SGLT2 inhibitors reduce hyperkalemia risk, allowing better optimization of mineralocorticoid receptor antagonists and other GDMT 6.

Integration with Other GDMT

SGLT2 inhibitors are now one of the four foundational medication classes for HFrEF (alongside ARNI/ACEi/ARB, beta-blockers, and mineralocorticoid receptor antagonists) 7, 8. The 2022 AHA/ACC/HFSA guidelines elevated SGLT2 inhibitors to Class 1 recommendation status for HFrEF 7, 8.

In the landmark trials, approximately 11-19% of patients were on sacubitril-valsartan, 7.5-12% had cardiac resynchronization therapy, and 26-31% had implantable cardioverter-defibrillators, with no treatment interactions observed 1. This confirms SGLT2 inhibitors work synergistically with all other HF therapies.

Bottom Line Algorithm

  1. Diagnose HFrEF (LVEF ≤40%)
  2. Check eGFR and diabetes status
  3. If eGFR ≥30 mL/min/1.73 m²: Start either dapagliflozin 10 mg daily OR empagliflozin 10 mg daily
  4. If eGFR 25-30 mL/min/1.73 m² with albuminuria: Prefer dapagliflozin 10 mg daily
  5. If eGFR 20-30 mL/min/1.73 m²: Consider empagliflozin 10 mg daily
  6. If eGFR <20 mL/min/1.73 m²: Insufficient evidence; avoid use
  7. Initiate early—do not wait for complete GDMT optimization
  8. Educate about GMI risk and sick day management
  9. Monitor eGFR at 1-3 months (expect temporary decline up to 15%)
  10. Continue indefinitely unless contraindications develop

References

Guideline

guidelines for treating heart failure.

Trends in Cardiovascular Medicine, 2025

Research

SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting.

European heart journal supplements : journal of the European Society of Cardiology, 2025

Related Questions

Can an SGLT‑2 inhibitor be initiated in a patient with heart failure with reduced ejection fraction and chronic liver disease who has an estimated glomerular filtration rate of 25 mL/min and a serum bicarbonate of 15 mEq/L?
What diabetes medications are safe for a patient with heart failure and chronic kidney disease, aside from sodium‑glucose cotransporter‑2 (SGLT2) inhibitors?
What are the benefits of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors in patients with heart failure with reduced ejection fraction?
Can spironolactone and a sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitor be initiated in a patient with heart failure with reduced ejection fraction who has loose bowel movements and moderate dehydration that is currently being corrected?
Are sodium-glucose co-transporter 2 (SGLT-2) inhibitors a class I therapy for heart failure with preserved ejection fraction?
Why would azithromycin be effective in viral infections?
What are the nurse practitioner‑specific recommendations for evaluating and managing chronic stress‑induced hypothalamic‑pituitary‑adrenal (HPA) axis dysregulation in patients with major depressive disorder (MDD)?
What is a simplified overview of parkinsonism, including its signs, causes, and treatment?
Which MRI protocol should be ordered for a patient with lumbar back pain radiating to the lower extremities and hip?
What are the adverse effects of discontinuing carbidopa‑levodopa therapy in a patient with Parkinson disease who refuses to take carbidopa?
How should a patient who started carbidopa‑levodopa two weeks ago and is experiencing nausea manage the medication without abruptly stopping it?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.